Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Ovarian Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Gemcitabine 29pembrolizumab 20Cisplatin 20Magnetic Resonance Spectroscopy 17Specimen Handling 16Mitomycin 10enfortumab vedotin 9durvalumab 9Cystoscopy 9avelumab 8Nivolumab 8Fluorouracil 8Carboplatin 8Radiation 7Cystectomy 6atezolizumab 5Transurethral Resection of Bladder 5Radiotherapy 5Mitozytrex 5Docetaxel 5Biopsy 5tremelimumab 4sacituzumab govitecan 4erdafitinib 4dehydroftorafur 4Platinum 4Immunoglobulin G 4Disulfides 41,2-diaminocyclohexaneplatinum II citrate 4disitamab vedotin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × RC48 antibody × 90 days × Clear all
NCT07608224 2026-05-27

HOPE-07-MIBC

West China Hospital

Phase 2/3 Not yet recruiting
240 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT05911295 2026-04-20

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Seagen Inc.

Phase 3 Active not recruiting
412 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡